Evgeniy M. Shilov

Evgeniy M. Shilov

Auto-generated profile, based on publicly available information

Evgeniy M. Shilov

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
ZKZh. D. Kobalava
Zh. D. Kobalava
MSMarina Shestakova
Marina Shestakova
IBI. N. Bobkova
I. N. Bobkova
MEM. A. Efremovtseva
M. A. Efremovtseva
ASA. M. Shutov
A. M. Shutov
The consensus was developed by experts from the Russian Scientific Medical Society of Internal Medicine, the Russian Society for the Prevention of Noncommunicable Diseases, the National Nephrology Association, the Professional Nephrology Association, the Russian Society of Cardiology, the Russian Medical Society for Arterial Hypertension, the Heart Failure Society, the National Atherosclerosis Society, the Russian Endocrinology Association, and the Russian Gerontology and Geriatrics Association.The expert consensus opinion was compiled on the basis of the relevant sections of national and international clinical guidelines on chronic kidney disease, prevention and treatment of atherosclerosis, hypertension, diabetes and heart failure.

13 December 2017 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
SMSergey A. Martynov
Sergey A. Martynov
MSMarina Shestakova
Marina Shestakova
ESEvgeniy M. Shilov
Evgeniy M. Shilov
MSMinara Sh. Shamkhalova
Minara Sh. Shamkhalova
OVOlga K. Vikulova
Olga K. Vikulova
ТПТрубицина Наталья Петровна
Трубицина Наталья Петровна
Background. Diabetes mellitus (DM) is a non-infectious disease with a high prevalence worldwide and is one of the most common causes of diabetic kidney disease (DKD). Anaemia is a well-known complication of chronic kidney disease (CKD) and has been estimated to affect one in three adults with DM. Aims. To evaluate the prevalence and severity of anaemia among patients with DKD and to compare the distribution of anaemia among patients with diabetic and non-diabetic CKD. Methods. A total of 2,015 patients with DM [n = 807 with type 1 DM (T1DM); n = 1,208 with type 2 DM (T2DM)] and 244 patients with biopsy-proven chronic glomerulonephritis (CGN) were selected. Patients with glomerular filtration rate (GFR) of 15 ml/min/1,73 m2 (stage 5 CKD) and treated by erythropoietin-stimulating agents and/or iron medication were not included. The presence of anaemia was defined as haemoglobin (Hb) of 130 g/l in men and 120 g/l in woman. GFR was calculated using the MDRD formula. CKD stages were defined based on stages 14 of CKD by KDOQI and KDIGO guidelines: stage 1 (GFR 90 ml/min/1.73 m2); stage 2 (GFR 6089 ml/min/1.73 m2); stage 3 (GFR 3059 ml/min/1.73 m2); stage 3a (4559 ml/min/1.73 m2); stage 3b (GFR 3044 ml/min/1.73 m2); stage 4 (GFR 1529 ml/min/1.73 m2). Results. Rates of anaemia were higher among patients with DM and DKD (38.8% and 22.6% for T1DM and T2DM, respectively) than diabetic patients without DKD (16.6% and 11.5%, respectively. Prevalence of anaemia by CKD stage increased from 23.3% in stage 1 to 80% in stage 4 among patients with T1DM, and from 16.9% to 81 % among patients with T2DM. The prevalence of anaemia was also higher among protoeinuric patients (53.9% and 34.4% for T1DM and T2DM, respectively) relative to microalbuminuric patients (29.4% and 17.6%, respectively). Anaemia prevalence was significantly greater in DKD due to T1DM (53.9%) than in CGN (19.7), and the rates did not differ based on stages of CKD. Conclusions. We found a two-fold higher rate of anaemia among patients with DM and CKD than patients with DM and non-DKD. In addition, we found that the frequency of anaemia depends on renal function (i.e., stage of CKD) and degree of albuminuria. Taken together, anaemia is highly prevalent among patients with T1DM and DKD compared with patients with chronic CGN, without differences in its severity.

24 January 2017 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
PDF file
KDK. A. Demyanova
K. A. Demyanova
NKN. L. Kozlovskaya
N. L. Kozlovskaya
LBL. A. Bobrova
L. A. Bobrova
LKL. V. Kozlov
L. V. Kozlov
SAS. S. Andina
S. S. Andina
РВРощупкина Светлана Васильевна
Рощупкина Светлана Васильевна
Background: The role of the alternative complement pathway (AP) abnormalities in the pathogenesis of aHUS is well studied. Clinical and morphological manifestations of atypical HUS and catastrophic APS are often similar. However, studies on the state of AP in patients with CAPS are virtually absent. Aims: The aim of our study was to assess the state of AP in patients with CAPS and aHUS. Patients and methods: The study enrolled 67 patients (pts) with a diagnosis of CAPS (28 pts) and aHUS (39 pts). Studies of the complement system are made of 10 pts with CAPS and 20 aHUS. Factor H, I, B, D content, functional activity of factor H, and complement components C3, C4 was determined in serum by ELISA kit. Results: Patients with CAPS and aHUS showed similar changes in complement biomarkers. The factor H level in the serum was significantly higher than the standard value. However, the specific activity of factor H reduced, mean rate 59% for aHUS and 26% for CAPS. The median value of factor D was twice higher than the normal range in both groups, indicating the activation of the AP. Conclusions: There are indications of an AP activation not only in pts with aHUS but in CAPS pts too. We suppose that the activity of factor H is a more sensitive indicator of complement system changes than factor H level. Patients with CAPS and aHUS have similar clinical and laboratory characteristics. However, CAPS is more severe, with the involvement of a larger number of vascular beds. Perhaps this is due to the double damaging effects on the endothelium ― of antiphospholipid antibodies (aPL) and activated complement. So we hypothesize that CAPS can be called aPL-mediated TMA in pts with a complement system defect.

21 August 2014 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
PDF file
TZT. Y. Zhirnova
T. Y. Zhirnova
EАE. E. Аchkasov
E. E. Аchkasov
OTO. M. Tsirulnikova
O. M. Tsirulnikova
ESE. M. Shilov
E. M. Shilov
ODO. B. Dobrovolskiy
O. B. Dobrovolskiy
Background: Aim of this study was to evaluate the role of physical rehabilitation to improve the quality of life (QOL) of people after kidney transplantation. Patients and methods: Analyzes the results of treatment of 57 recipients (mean age 35±9,65 years) donor kidney at different times of the postoperative period. Depending on the physical rehabilitation program allocated 3 groups of patients: group II — physical rehabilitation was carried out only in the first week after surgery to prevent early postoperative complications, in group I — during the year; in group III combined 30 relatively healthy people do not need an organ transplant and with a mean age 33,7±8,7 years, leading a normal life, not engaged in regular recreational physical culture. Quality of life was assessed using a questionnaire SF36 at 1, 3, 6 and a 12 months after surgery. Results: One year after surgery in both groups compared with preoperative indicators marked improvement according to all scales of the questionnaire. However, in group I indicators of quality of life were higher than in group II from 11,4 to 19,7%, and even some items questionnaire SF-36 is higher than in group III which is associated with the physical rehabilitation. Conclusion: It has been shown that exercises is an important component of treatment and rehabilitation after kidney transplantation and help improve both the psychological and the physical component of quality of life.

10 October 2025 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ESE. V. Shlyakhto
E. V. Shlyakhto
GAG. P. Arutyunov
G. P. Arutyunov
MBM. M. Batyushin
M. M. Batyushin
SVSvetlana Villevalde
Svetlana Villevalde
NZN. E. Zvartau
N. E. Zvartau
ГАГ. Г. Арутюнов
Г. Г. Арутюнов
Aim. To describe the detection rate of chronic kidney disease (CKD) in patients with hypertension (HTN) and markers of CKD without concomitant diabetes and symptomatic heart failure, as well as to describe the clinical and demographic characteristics and features of therapy in the overall cohort and a subgroup with verified CKD.Material and methods. The article presents an interim analysis of data from a prospective observational multicenter study of patients with HTN and CKD in the Russian Federation (PRIORITY-CKD).Results. Data from the first 3249 patients included in the study were analyzed. In 2592 (79,8%) patients with HTN and CKD markers, the diagnosis of CKD was confirmed during the study as follows: in 1380 (42,5%) at Visit 1 and in 1212 (37,3%) at Visit 2. In 2488 (96%) cases, only the estimated glomerular filtration rate was used as the criteria for the diagnosis of CKD. Only in 12 patients (0,5%) albuminuria or proteinuria (alone or together with other CKD markers) was used as diagnostic criteria for CKD diagnosis. Cases of overdiagnosis (12,6%) and underdiagnosis (0,4%) of CKD were identified. In the overall cohort and the subgroup with verified CKD, women predominated (61,6/62,1%), while the median duration of HTN was 9 and 10 years, respectively. More than half of the patients had stage III HTN and very high cardiovascular risk. A high rate of metabolic risk factors (overweight, dyslipidemia, abdominal obesity) and atherosclerotic cardiovascular diseases was noted. Coronary artery disease was observed in a third of patients in the overall cohort and the CKD subgroup. Uncontrolled HTN (systolic BP ≥140 and/or diastolic BP ≥90 mm Hg despite antihypertensive therapy) and resistant HTN were detected in 42,5% and 6,7% of patients in the overall cohort, while in the subgroup with CKD in 42,1% and 7,3%, respectively. Combination antihypertensive therapy after Visit 1 was received by 78,8% of patients in the examined cohort. Only in 21,4% of cases, sodium-glucose cotransporter-2 inhibitors were prescribed after verification of the CKD diagnosis.Conclusion. In the Russian population, the diagnosis of CKD was confirmed in 79,8% of patients with HTN and CKD markers. Albuminuria/proteinuria was assessed extremely rarely. Cases of overdiagnosis and underdiagnosis of CKD were identified. A high rate of uncontrolled HTN and a serious burden of atherosclerotic cardiovascular diseases were observed in the overall cohort and the subgroup with CKD. After CKD verification, a suboptimal increase in the prescription of sodiumglucose cotransporter-2 inhibitors was noted.

26 January 2026 in Nephrology (Saint-Petersburg)
Verified
Journal Article
Closed access
ESE. M. Shilov
E. M. Shilov
AYA. M. Yesayan
A. M. Yesayan
NPN. Yu. Petrova
N. Yu. Petrova
DAD. V. Artemov
D. V. Artemov
MBM. M. Batyushin
M. M. Batyushin
MSM. M. Shilova
M. M. Shilova
Chronic kidney disease (CKD) is the fifth globally socially significant chronic non–communicable disease recognized by WHO. The prevalence of CKD in the world ranges from 10 to 20 % and outstrips the prevalence of diabetes mellitus and cardiovascular diseases (850, 600, and 560 million people, respectively). By 2040, CKD will become the 5th cause of premature mortality, ahead of cancer and diabetes mellitus. In Russia, the prevalence of CKD in risk groups (hypertension, chronic heart failure, and diabetes mellitus) is at least 16 % of the country's population. CKD significantly increases the medical, social, and financial burden on the state budget, a significant part of which is spent on saving the lives of patients who have survived to the end stage renal disease, such as kidney replacement therapy (dialysis, kidney transplantation) and treatment of comorbid conditions. CKD makes a huge contribution to premature mortality. Most patients die from cardiovascular complications (strokes, heart attacks, heart failure) before the development of the terminal stage of the disease. Early detection of the disease will improve the ability to work and enhance the quality of life, as well as increase its duration. Special attention should be paid to risk groups, primarily patients with cardiovascular diseases and diabetes mellitus. The current management strategy for CKD patients is prevention and screening for early manifestations of CKD (decreased glomerular filtration rate and albuminuria), followed by the use of triple cardio–reno-protective therapy (RAAS inhibitors, glyphlozines, synthetic mineralocorticoid receptor blockers), which can slow the progression to the terminal stage of the disease and reduce mortality from cardiovascular complications. Preserving and prolonging the lives of CKD patients requires appropriate government organizational measures – in essence, changing the existing healthcare model focused on the terminal stages of the disease to a model aimed at prevention, early detection, and slowing the progression of CKD